Business
HYTN Drug Establishment Licence Expanded to Include Active Pharmaceutical Ingredients and Pharmaceutical Oils
VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC Pink: HYTNF) (“HYTN” or the “Company”), a pharmaceutical manufacturer specializing in products containing psychoactive and psychotropic compounds, is pleased to announce that its Health Canada Drug Establishment Licence (DEL) has been amended following a comprehensive Good Manufacturing Practices (GMP) inspection of its Kelowna, British Columbia Facility. Under the amended licence, issu
About this update from Hytn Innovations Inc
[{"type":"image","alt":"HYTN Innovations Inc.","displaySize":"","headline":null,"caption":"HYTN Innovations Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":267,"height":91,"url":"https://media.zenfs.com/en/globenewswire.com/d0d2c55d487605e813bedcd12be5d8b1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WwJCiVlVdiZV0YtQRlnsrw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0Mw--/https://media.zenfs.com/en/globenewswire.com/d0d2c55d487605e813bedcd12be5d8b1","width":267,"height":91},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/WwJCiVlVdiZV0YtQRlnsrw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0Mw--/https://media.zenfs.com/en/globenewswire.com/d0d2c55d487605e813bedcd12be5d8b1","width":267,"height":91}},"lazy":false},{"type":"text","content":"VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC Pink: HYTNF) (“HYTN” or the “Company”), a pharmaceutical manufacturer specializing in products containing psychoactive and psychotropic compounds, is pleased to announce that its Health Canada Drug Establishment Licence (DEL) has been amended following a comprehensive Good Manufacturing Practices (GMP) inspection of its Kelowna, British Columbia Facility.","length":468,"tagName":"p"},{"type":"text","content":"Under the amended licence, issued by Health Canada, HYTN is now authorized to fabricate, package, and label non-sterile Active Pharmaceutical Ingredients (API) in both solid and non-solid forms, and adds Pharmaceutical Oil as an authorized finished dosage form. The updated scope of the license expands the Company's GMP manufacturing activities and supports its ability to service both pharmaceutical and cannabinoid supply chains subject to applicable product-specific, customer-specific, import, release, and jurisdictional requirements.","length":544,"tagName":"p"},{"type":"text","content":"The Company notes that the amended licence, together with its previously announced Cannabis Drug Licence, Cannabis Processing Licence, and expanded DEL dosage form authorizations, permits additional regulated manufacturing activities at HYTN’s Kelowna facility. These activities may support HYTN’s participation in regulated drug-development and pharmaceutical manufacturing programs involving cannabinoid-derived inputs and finished dosage forms, where applicable product-specific, customer-specif...